**Table 1.** | Clinical characteristics of the 119 patients studied, stratified according to HCV exposure. Pvalues A) Comparison of the 3 study groups. B) HIV+ vs. HIV+HCV-. C) HIV+ vs. HIV+HCV+. D) HIV+/HCV- vs. HIV+HCV.

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | | **+HIV** | **HIV+HCV-** | **HIV+HCV+** | **pvalue** | | | |
|  |  | |  |  |  | A | B | C | D |
| n |  | | 36 | 36 | 47 |  |  |  |  |
| Sex |  | |  |  |  | 0.696 | 0.814 | 0.504 | 0.823 |
| Male | | 18/36 (50.00%) | | 20/36 (55.56%) | 28/47 (59.57%) |  |  |  |  |
| Risk (%) |  | |  |  |  | <0.001 | <0.001 | <0.001 | 0.769 |
| IDU  IDU+Sexual  Sexual  Vertical | | 0/30 (0.00%) | | 21/32 (65.62%) | 26/44 (59.09%) |  |  |  |  |
| 0/30 (0.00%) | | 1/32 ( 3.12%) | 1/44 ( 2.27%) |  |  |  |  |
| 30/30 (100.00%) | | 10/32 (31.25%) | 15/44 (34.09%) |  |  |  |  |
| 0/30 (0.00%) | | 0/32 (0.00%) | 2/44 ( 4.55%) |  |  |  |  |
| HIV clinical transmission |  | |  |  |  | 0.158 | 0.060 | 0.142 | 0.723 |
| A  B  C | | 23/33 (69.70%) | | 13/32 (40.62%) | 22/45 (48.89%) |  |  |  |  |
| 5/33 (15.15%) | | 8/32 (25.00%) | 8/45 (17.78%) |  |  |  |  |
| 5/33 (15.15%) | | 11/32 (34.38%) | 15/45 (33.33%) |  |  |  |  |
| HCV Genotype |  | |  |  |  | 0.443 | 1.000 | 1.000 | 0.443 |
| 1a  1b  2  3  4 | | 0/0 (0.00%) | | 0/2 (0.00%) | 17/42 (40.48%) |  |  |  |  |
| 0/0 (0.00%) | | 1/2 (50.00%) | 9/42 (21.43%) |  |  |  |  |
| 0/0 (0.00%) | | 0/2 (0.00%) | 2/42 ( 4.76%) |  |  |  |  |
| 0/0 (0.00%) | | 0/2 (0.00%) | 2/42 ( 4.76%) |  |  |  |  |
| 0/0 (0.00%) | | 1/2 (50.00%) | 12/42 (28.57%) |  |  |  |  |
| IL28b |  | |  |  |  | 0.001 | 0.025 | 0.082 | <0.001 |
| CC  CT  TT | | 19/36 (52.78%) | | 27/36 (75.00%) | 14/45 (31.11%) |  |  |  |  |
| 16/36 (44.44%) | | 6/36 (16.67%) | 25/45 (55.56%) |  |  |  |  |
| 1/36 ( 2.78%) | | 3/36 ( 8.33%) | 6/45 (13.33%) |  |  |  |  |
|  |  | |  |  |  |  |  |  |  |
| CD4+ T cells (cél/mm3) | | 833.00 [697.42, 1062.00] | | 732.70 [560.70, 916.65] | 703.80 [529.00, 1033.80] | 0.042 | 0.028 | 0.029 | 0.945 |
| CD4 + T cells (%) | | 38.28 [31.50, 44.75] | | 35.00 [31.00, 40.00] | 33.00 [27.00, 41.38] | 0.275 | 0.166 | 0.165 | 0.756 |
| CD8+ T cells (cél/mm3) | | 905.50 [795.42, 1244.50] | | 870.50 [636.50, 1104.75] | 790.00 [634.00, 1048.00] | 0.527 | 0.484 | 0.269 | 0.806 |
| CD8+ T cells (%) | | 37.92 [33.64, 44.08] | | 36.05 [31.62, 43.14] | 42.00 [36.00, 45.00] | 0.159 | 0.370 | 0.215 | 0.083 |

**Statistics**: Categorical variables were expressed as absolute numbers (%) while continuous variables were expressed as medians and interquartile range. Statistical inference was performed with Fisher's exact test for categorical variables and with the Kruskal-Wallis test for continuous variables. **Abbreviations**: HIV - Human immunodeficiency virus, HCV - Hepatitis C virus, IDU - Injecting drug users.

**Table 2. |** Biochemical and metabolic characteristics of the 119 patients, stratified according to their HCV exposure. Pvalues A) Comparison of the 3 study groups. B) HIV+ vs. HIV+HCV-. C) HIV+ vs. HIV+HCV+. D) HIV+/HCV- vs. HIV+HCV.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | HIV+ | HIV+HCV- | HIV+HCV+ | pvalue |  |  |  |
| n | 36 | 36 | 47 | A | B | C | D |
| Age (years) | 49.00 [41.50, 55.50] | 51.50 [48.00, 55.00] | 49.00 [43.50, 53.00] | 0.256 | 0.391 | 0.596 | 0.086 |
| Time of HIV infection (months) | 228.07 [89.89, 266.00] | 275.70 [142.72, 335.41] | 256.10 [110.69, 323.35] | 0.140 | 0.056 | 0.167 | 0.459 |
| Weight (kg) | 67.00 [61.10, 79.00] | 74.75 [62.62, 80.75] | 63.00 [57.00, 73.30] | 0.011 | 0.504 | 0.032 | 0.006 |
| BMI | 24.75 [22.44, 27.12] | 24.72 [22.07, 27.89] | 22.35 [20.83, 25.50] | 0.024 | 0.980 | 0.021 | 0.026 |
| Glucose | 92.00 [86.00, 96.00] | 93.00 [87.75, 101.25] | 88.00 [85.50, 96.00] | 0.537 | 0.500 | 0.663 | 0.277 |
| Glucose > 110 | 2/25 ( 8.00%) | 2/20 (10.00%) | 3/35 ( 8.57%) | 1.000 | 1.000 | 1.000 | 1.000 |
| Total cholesterol | 184.00 [172.00, 205.00] | 193.00 [186.00, 215.50] | 185.00 [166.00, 203.00] | 0.259 | 0.434 | 0.375 | 0.112 |
| cholesterol > 200 | 10/25 (40.00%) | 8/19 (42.11%) | 9/33 (27.27%) | 0.465 | 1.000 | 0.399 | 0.360 |
| LDL | 115.50 [100.50, 144.25] | 114.50 [100.25, 128.75] | 104.00 [92.00, 124.00] | 0.338 | 0.760 | 0.210 | 0.249 |
| LDL > 130 | 9/24 (37.50%) | 4/18 (22.22%) | 6/33 (18.18%) | 0.255 | 0.333 | 0.133 | 0.727 |
| HDL | 46.00 [37.50, 54.50] | 49.50 [41.25, 58.25] | 50.00 [40.00, 61.00] | 0.692 | 0.500 | 0.438 | 1.000 |
| TG | 116.00 [97.25, 178.75] | 127.00 [109.75, 173.25] | 120.00 [79.00, 180.00] | 0.396 | 0.542 | 0.401 | 0.211 |
| TG high | 5/24 (20.83%) | 4/18 (22.22%) | 4/33 (12.12%) | 0.576 | 1.000 | 0.470 | 0.430 |
| LDL/HDL | 2.43 [2.12, 2.94] | 2.32 [1.89, 2.99] | 2.23 [1.68, 2.85] | 0.449 | 0.571 | 0.237 | 0.500 |
| AI (%) | 3.95 [3.67, 5.07] | 3.99 [3.29, 4.74] | 3.71 [3.12, 4.41] | 0.344 | 0.589 | 0.167 | 0.406 |
| AI low | 17/24 (70.83%) | 14/18 (77.78%) | 27/33 (81.82%) | 0.562 | 0.731 | 0.357 | 0.727 |
| AI moderate | 7/24 (29.17%) | 4/18 (22.22%) | 6/33 (18.18%) | 0.562 | 0.731 | 0.357 | 0.727 |
| AIP | 0.89 [0.69, 1.43] | 0.95 [0.72, 1.47] | 0.97 [0.31, 1.24] | 0.544 | 0.831 | 0.427 | 0.323 |
| AIP high | 23/24 (95.83%) | 16/18 (88.89%) | 28/33 (84.85%) | 0.453 | 0.567 | 0.384 | 1.000 |
| LCI | 60.00 [35.84, 122.80] | 66.02 [43.43, 95.39] | 42.00 [23.77, 73.98] | 0.206 | 0.970 | 0.158 | 0.127 |
| GOT (AST) | 24.00 [22.00, 27.00] | 23.00 [19.50, 26.50] | 36.00 [28.75, 46.25] | <0.001 | 0.284 | <0.001 | <0.001 |
| GOT > 40 | 2/25 ( 8.00%) | 0/19 (0.00%) | 12/36 (33.33%) | 0.002 | 0.498 | 0.030 | 0.004 |
| GPT (ALT) | 28.00 [23.00, 33.00] | 21.50 [17.50, 25.00] | 45.50 [32.00, 62.50] | <0.001 | 0.004 | <0.001 | <0.001 |
| GPT > 40 | 4/25 (16.00%) | 0/20 (0.00%) | 22/36 (61.11%) | <0.001 | 0.117 | 0.001 | <0.001 |
| GGT | 26.00 [21.00, 36.50] | 30.50 [25.25, 38.00] | 52.00 [33.00, 89.25] | <0.001 | 0.423 | <0.001 | 0.002 |
| GGT > 50 | 3/23 (13.04%) | 0/18 (0.00%) | 17/32 (53.12%) | <0.001 | 0.243 | 0.004 | <0.001 |
| APRI | - | 0.35 [0.30, 0.44] | 0.62 [0.50, 0.67] | 0.121 | - | - | 0.142 |
| FIB-4 | - | 1.22 [1.18, 1.31] | 1.56 [1.39, 1.73] | 0.053 | - | - | 0.061 |
| ALP | 78.00 [66.00, 94.00] | 93.50 [68.50, 103.75] | 85.00 [64.00, 98.00] | 0.374 | 0.205 | 0.431 | 0.362 |
| Albumin | 4.00 [4.00, 4.30] | 4.50 [4.50, 4.50] | 4.40 [4.10, 4.40] | 0.200 | 0.324 | 0.399 | 0.107 |
| Vitamin D | 24.00 [21.75, 37.00] | 12.00 [8.00, 13.00] | 22.00 [14.00, 27.00] | 0.014 | 0.013 | 0.271 | 0.032 |
| Calcium (Ca2+) | 9.40 [9.10, 9.80] | 9.50 [9.20, 9.70] | 9.40 [9.00, 9.70] | 0.672 | 0.877 | 0.539 | 0.401 |
| Phosphorous (P) | 3.40 [3.20, 3.90] | 3.40 [3.20, 3.90] | 3.40 [2.95, 3.65] | 0.528 | 0.761 | 0.297 | 0.453 |
| Iron (Fe2+) | - | 72.00 [65.00, 88.50] | 78.00 [78.00, 78.00] | 0.655 | - | - | 1.000 |
| Leukocytes (x103) | 6.94 [5.61, 8.60] | 6.98 [5.71, 7.97] | 6.74 [5.74, 7.64] | 0.851 | 0.991 | 0.600 | 0.697 |
| Red blood cells | 4.83 [4.80, 4.98] | - | 4.70 [4.33, 5.11] | 0.406 | - | 0.434 | - |
| Hemoglobine | 14.90 [13.80, 15.70] | 15.15 [13.57, 15.60] | 15.00 [14.47, 15.93] | 0.419 | 0.991 | 0.165 | 0.488 |
| Hematocrit (%) | 47.00 [45.70, 50.05] | - | 47.40 [43.33, 48.33] | 0.379 | - | 0.406 | - |
| Platelets (x103) | 235.00 [219.00, 275.00] | 224.00 [194.00, 290.25] | 218.50 [191.25, 251.25] | 0.162 | 0.444 | 0.065 | 0.317 |
| LHD | 172.00 [162.50, 203.50] | - | 178.00 [170.00, 197.75] | 0.845 | - | 0.887 | - |
|  |  |  |  |  |  |  |  |

Statistics: Categorical variables were expressed as absolute numbers (%) while continuous variables were expressed as medians and interquartile range. Statistical inference was performed with Fisher's exact test for categorical variables and with the Kruskal-Wallis or Wilcoxon test for continuous variables. **Abbreviations:** HIV - Human Immunodeficiency Virus, HCV - Hepatitis C Virus, BMI - Body Mass Index, LDL - Low Density Lipoprotein, HDL - High Density Lipoprotein, TG - Triglycerides, AI - Atherogenic Index (Low risk cut-off values <5% for men and <4.5% for women, and moderate risk 5-9% for men and 4. 5-7% for women), AIP - Plasma Atherogenic Index (High risk cut-off values > 0. 21), LCI - Lipoprotein Combined Index (Calculated with the ratio Cholesterol\*TG\*LDL), GOT - aspartate aminotransferase, GPT - alanine aminotransferase, GGT - gamma-glutamyl transferase, APRI - GOT/Platelet Index, FIB-4 - Fibrosis Index 4, ALT - alkaline phosphatase, LHD - lactate dehydrogenase.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |